Table 1.
A list of miRNA-mimics examined for their cancer therapeutic potential in pre-clinical studies*
| miRNA | Year | Delivery system | Cancer | Mechanisms (Target genes) | Target genes | Model | Methodology | Ref |
|---|---|---|---|---|---|---|---|---|
| miR-26 | 2009 | Adeno-associated virus | Liver | G1 cell cycle arrest | CCND2, CCNE2 | In vivo | tet-oMYC;LAP-tTA | (36) |
| miR-34a | 2010 | Nanoparticles | Lung | Tumor load reduction | Survivin | In vivo | Intravenous | (60) |
| miR-34a & 143/145 | 2011 | Nanoparticles | Pancreatic | Apoptosis enhancement | SIRT1, CD44, ALDH1, KRAS2, RREB1 | In vivo | Xenograft | [73] |
| miR-34a | 2012 | Nanoparticles | Neuroblastoma | Vascularization reduction | TIMP2 | In vivo | Xenograft | (58) |
| miR-107 | 2012 | Nanoparticles | Head and neck | Cancer initiation cell reduction | NANOG, OCT3/4, SOX4 | In vivo | Xenograft | (68) |
| miR-155 | 2012 | Nanoparticles | Ovarian | Immunosuppressive mediator suppression | - | In vivo | Orthotopic | (126) |
| miR-5, 10, 7 | 2012 | Adeno-associated virus | Retinal | Endogenous VEGF suppression | VEGF | In vivo | Intramuscular | (70) |
| Let-7a | 2013 | Nanoparticles | Lung | Proliferation reduction | RAS | In vitro | 3D tumor growth assay | (62) |
| miR-29b | 2013 | Nanoparticles | Leukemia | Growth reduction | DNMTs, CDK6, SP1, KIT, FLT3 | In vivo | Intravenous | (125) |
| miR-200c | 2013 | Nanoparticles | Ovarian, Lung, Real Breast | Tumor angiogenesis reduction | IL-8 and CXCL1 | In vivo | Intrapulmonary | (10) |
| miR-203 | 2013 | Nanoparticles | Esophageal | Proliferation and migration reduction | Ran, ΔNp63 | In vitro | Cell lines | (65) |
| miR-1 | 2014 | Nanoparticles | Glioblastoma | GBM sphere reduction | MET, EGFR | In vitro | Patient derived stem cells | (69) |
| miR-16 | 2014 | Nanoparticles | Gastric | Apoptosis enhancement | - | In vivo | Xenograft | (123) |
| miR-34a | 2014 | Stable lipid particles | Multiple myeloma | Apoptosis enhancement | ERK2, AKT | In vivo | Orthotopic | (59) |
| miR-34a | 2014 | Nanoparticles | Breast | Migration reduction | NOTCH 1 | In vivo | Xenograft | (57) |
| Let-7b | 2015 | Neutral lipid emulsion | Lung | Tumor growth reduction | MYC | In vivo | Kras; P53 model | (55) |
| miR-34a | 2015 | Neutral lipid emulsion | Lung | Proliferation reduction | MET, MYC | In vivo | Kras; P53 model | [69] |
| miR-34a | 2015 | Nanoparticles | Prostate | Non-canonical autophagy enhancement | MET, AXL, MYC | In vivo | Femur | (56) |
| miR-145 | 2015 | Lipofectamine RNAi max | Bladder | Apoptosis enhancement | MYC, SOCS7, FSCN1, CDH1 | In vivo | Xenograft | [79] |
| miR-145 | 2015 | PEI nanocarrier | Prostate | Proliferation reduction | FSCN1, MYC, IGFIR | In vivo | Xenograft | [78] |
| miR-495 | 2015 | Neutral lipid emulsion | Lung | Tumor burden and Proliferation reduction | - | In vivo | Xenograft | (122) |
| miR-514-3p | 2015 | Nanoparticles | Neuroblastoma | Apoptosis enhancement | Survivin | In vivo | Xenograft | (124) |
| Let-7g | 2016 | Nanoparticles | Liver | Cell survival enhancement | MYC | In vivo | Orthotopic | [175] |
| miR-542 | 2016 | Nanoparticles | Breast | Apoptosis enhancement | P53 activation | In vitro | Cell lines | [176] |
| miR-34a | 2017 | Nanoparticles | Colon | Apoptosis enhancement | BCL-2 | In vivo | Xenograft | [177] |
| miR-542 | 2017 | Nanoparticles | Gastric | Apoptosis enhancement | P53 activation | In vivo | Xenograft | [178] |
| miR-7 | 2018 | Nanoparticles | Ovary | Chemosensitization enhancement | EGFR/ERK pathway | In vivo | Xenograft | [179] |
| miR-20a | 2018 | Nanoparticles | Colon | Liver metastasis reduction | ARHGA P1 and E2F1 | In vivo | Liver metastasis model | [180] |
| miR-27a | 2018 | Nanoparticles | Liver | Proliferation reduction | FOXO1, PPAP-γ | In vivo | Xenograft | [181] |
| miR-375 | 2018 | Nanoparticles | Liver | Autophagy and Proliferation reduction | - | In vivo | Xenograft | [182] |
| miR-27 | 2019 | Nanoparticles | Liver | Apoptosis enhancement | FOXO1, PPAR | In vivo | Xenograft | [183] |
| miR-122 | 2019 | Nanoparticle | Liver | Apoptosis enhancement | ADAM17 | In vivo | Xenograft | [184] |
| miR-125b | 2019 | Nanoparticles | Ovarian | Increased Macrophage repolarization | - | In vivo | Orthotopic | [185] |
| miR-139-5p | 2019 | Nanoparticles | Colon | Proliferation and migration reduction | - | In vivo | Xenograft | [186] |
| miR-143 | 2019 | Nanoparticles | Prostate | Proliferation reduction | UPAR | In vivo | Xenograft | [187] |
| miR-212 | 2019 | Nanoparticles | Pancreas | Chemosensitization enhancement | USP9X | In vivo | PDX | [188] |
| miR-660 | 2019 | Nanoparticles | Lung | Growth reduction | MDM2, p-53 | In vivo | PDX | [189] |
| miR-873 | 2019 | Nanoparticles | Pancreas, breast | Growth reduction | KRAS | In vivo | Xenograft | [190] |
| miR-34a | 2020 | Nanoparticles | Breast | Tumor growth reduction | - | In vivo | Xenograft | [191] |
*
Chronologically listed